IMMX

Latest SEC Filings & News for IMMX

2 most recent filings and news items mentioning IMMX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/IMMX/news?limit=20"

Pull IMMX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

OfferingMay 21, 2026Negative

Immix Biopharma prices 16.8M share offering at $0.01 per share

Immix Biopharma is conducting an underwritten public offering of approximately 16.8 million shares of common stock at $0.01 per share with Morgan Stanley as lead underwriter. The offering provides capital for the biopharmaceutical company under its existing shelf registration sta

View filing at SEC.gov →

RegulatoryMay 21, 2026Positive

Immix Biopharma reports 95% complete response rate in NEXICART-2 trial

Immix announced interim results from its NEXICART-2 Phase 2 trial showing a 95% complete response rate (19 of 20 patients) in relapsed/refractory AL Amyloidosis patients treated with NXC-201, with all CRs achieved within one year and no relapses observed. The company plans to ini

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.